About Vevo Therapeutics
Vevo Therapeutics specializes in drug discovery by using advanced AI models and its Mosaic platform to generate high-resolution in vivo data, which studies drug interactions within living organisms. This method allows them to identify new drug targets and candidates that traditional approaches might miss. Unlike competitors, Vevo's focus on single-cell RNA profiling from diverse patient samples enables a more comprehensive understanding of drug efficacy. The company's goal is to enhance drug development processes and uncover better treatments for a wider range of patients.
San Francisco, CaliforniaHeadquarters
2022Year Founded
$11.7MTotal Funding
SEEDCompany Stage
AI & Machine Learning, BiotechnologyIndustries
11-50Employees
Risks
Intense competition from other AI-driven drug discovery platforms.
Rapid technological advancements may render current platform obsolete.
Data privacy concerns could lead to regulatory scrutiny.
Differentiation
Vevo uses Mosaic platform for high-resolution in vivo drug discovery.
AI models enhance Vevo's drug discovery by analyzing diverse patient data.
Single-cell RNA profiling offers insights into drug efficacy across patient populations.
Upsides
Rising demand for single-cell RNA sequencing boosts Mosaic platform's relevance.
AI-driven drug discovery is gaining traction in pharmaceutical industry.
Partnerships with academic institutions provide access to cutting-edge research.
Funding
Total raised$11.67 M
Latest valuation$60.00 M
StageSEED
SEED
11/30/2022$12
$60.00 M